Small-Molecule MASP-2 Inhibitors for Selective Lectin Pathway Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for small molecule compounds that can selectively inhibit mannan-binding lectin-associated serine protease-2 (MASP-2) to treat MASP-2 complement pathway-associated diseases and disorders without interfering with the antibody-dependent classical complement activation pathway, which is critical for the acquired immune response.
Innovation Solution
Development of small molecule inhibitors that interact specifically with the MASP-2 serine protease domain through various intermolecular interactions, including hydrogen bonds, ionic interactions, π-π interactions, and van der Waals contacts, to inhibit MASP-2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to selectively inhibit MASP-2, then the lectin pathway complement activity is blocked providing therapeutic benefits, but there is a risk of interfering with the classical complement activation pathway which is critical for acquired immune response
Solution Approach 1:
The patent applies local quality by designing small molecule inhibitors with specific molecular structures that target only the MASP-2 serine protease domain. The compounds are engineered to interact with specific amino acid residues in the MASP-2 active site through hydrogen bonds, ionic interactions, π-π interactions, and van der Waals contacts, ensuring selective inhibition of MASP-2 while leaving the classical complement pathway components (C1q, C1r, C1s) unaffected.
Solution Approach 2:
The patent segments the complement system into distinct functional components and targets only the MASP-2 component for inhibition. By focusing specifically on the lectin pathway's serine protease domain and designing inhibitors that bind to its unique active site architecture, the patent achieves selective blockade of MASP-2 activity while preserving the integrity and function of the classical complement activation pathway.
2Reliability
If fully human monoclonal antibodies targeting MASP-2 are used, then high affinity binding and lectin pathway blockade is achieved, but the complexity of administration and potential immunogenicity increase
Solution Approach 1:
The patent replaces the biological mechanism of monoclonal antibodies with a chemical mechanism using small molecule compounds. Instead of using large protein-based antibodies that require complex administration protocols and carry risks of immunogenicity, the patent employs synthetic small molecules that can be administered more simply and do not trigger immune responses against the therapeutic agent itself.
Solution Approach 2:
The patent employs small molecule compounds that are chemically synthesized and can be produced more cost-effectively than monoclonal antibodies. These small molecules have simpler pharmacokinetic profiles and can be manufactured using established chemical synthesis methods, reducing both production complexity and administration burden compared to biologic antibody therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small molecule inhibitors effectively block the lectin pathway complement activity, providing therapeutic benefits for MASP-2-associated diseases and disorders while preserving the functionality of the classical complement activation pathway.
Implementation Method 1
The small molecule inhibitors effectively block the lectin pathway complement activity through various intermolecular interactions, including hydrogen bonds
Implementation Method 2
The small molecule inhibitors effectively block the lectin pathway complement activity through various intermolecular interactions, including ionic interactions
Implementation Method 3
The small molecule inhibitors effectively block the lectin pathway complement activity through various intermolecular interactions, including π-π interactions
Implementation Method 4
The small molecule inhibitors effectively block the lectin pathway complement activity through various intermolecular interactions, including van der Waals contacts
Data Source
AI summary
The present disclosure provides, intra alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.